Navigation Links
TriReme Medical Announces $17 Million Series D Financing
Date:10/11/2010

PLEASANTON, Calif., Oct. 11 /PRNewswire/ -- TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing.  The financing was led by Bio*One Capital, a subsidiary of Singapore based EDB Investments ('EDBI') with strong support from current investors, Three Arch Partners and Adams Street Partners.  "We are delighted to have Bio*One join our group of sophisticated blue chip investors who share our vision of developing innovative catheter and stent technology for coronary and peripheral interventional procedures," said Eitan Konstantino, Ph.D., President and CEO of TriReme Medical, Inc.  "This investment will allow us to ramp up our commercial activities worldwide, continue to develop internal R&D programs and pursue key regulatory approvals for our products in large markets such as the US, Japan, and China."

Ms Chu Swee-Yeok, CEO EDBI and Bio*One Capital said, "We are impressed with the global vision of TriReme's management team and its ability to rapidly develop and gain regulatory approvals for its novel catheter technologies.  Its strategy of positioning itself in Singapore will allow the company to tap on the fast growing Asian markets and enhance its competitiveness and reach." Mark Wan, General Partner at Three Arch Partners added, "This investment will allow TriReme to maximize the value of its R&D portfolio by providing for expansion of regulatory approvals and the creation of a commercial infrastructure that will drive revenue growth in the coming years."

About TriReme Medical, Inc.

Based in Pleasanton, California, TriReme Medical, Inc. (TMI) is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease.  The Company's novel ballo
'/>"/>

SOURCE TriReme Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. TriReme Medical, Inc. Receives FDA 510K Clearance for Glider(TM) PTA Balloon Catheter
2. TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
3. Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS)
4. Varian Medical Systems Schedules Fourth Quarter FY2010 News Release and Conference Call
5. Cantel Medical Corp. to Hold Conference Call to Discuss Fourth Quarter and Fiscal 2010 Results
6. Concentric Medical Announces Commercial Launch of Trevo™ in Europe
7. CSA Medical Selected to Present at AdvaMed 2010: The MedTech Conference
8. Nonin Medical Announces Its Second-Generation Wrist-Worn Device for European Distribution: Delivering Reliability in the Widest Range of Patient Populations and Clinical Settings
9. Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
10. DSM Biomedical to be Key Contributor at the Surfaces in Biomaterials Foundations 2010 BioInterface Symposium and Workshop
11. International Menopause Society Calls Upon Medical Community to Improve the Vaginal Health of Postmenopausal Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... TRU-016 Produces Significant Anti-Tumor Activity and Long-Term Tumor ... Regression ... Pharmaceuticals Inc.,(Nasdaq: TRBN ) today announced presentation of ... activity and induces,significant long-term tumor eradication in a human ...
... Encouraging Results for a Potential New Front-Line Treatment ... ... Genzyme Corp.,(Nasdaq: GENZ ) reported preliminary data today from a ... as a single agent in previously untreated, older adult,patients with acute ...
Cached Medicine Technology:Trubion Announces Presentation of Positive TRU-016 Data at ASCO 2Trubion Announces Presentation of Positive TRU-016 Data at ASCO 3Trubion Announces Presentation of Positive TRU-016 Data at ASCO 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 3Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 5Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 6Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 7Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 8
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... in Mexico support innovations to extend the local, productive impact of remittances shines spotlight ... ... Mexico and the US. - Broad, support in communities of origin for the ... from the US. -, Family members in Mexico would encourage senders to ...
... bill pending in the,state Senate could address Pennsylvania,s ... thousands who lack health insurance, a top Department,of ... Joined by approximately 250 nursing students and ... Bureau of Professional and,Occupational Affairs Commissioner Basil Merenda ...
... Touch with Reality, MANHATTAN BEACH, Calif., May 7 ... began in 2006 continues,today with open hearings and fact-finding ... of examining how homecare and nursing home,workers in the ... have the greatest strength to win for their families ...
... Final results of sub-analyses of dose-titration study and long-term, ... open-label study presented today, ... seen in children, Attention Deficit Hyperactivity Disorder,(ADHD) is now known to ... the lifespan(1). In the US, the overall,prevalence of ADHD in adults ...
... For the first time, researchers from the University of ... dendritic cells that are key to asthma and allergy-related ... more effective drugs to treat allergic disorders and asthma, ... of the journal Nature Medicine. , Dendritic cells are ...
... on Hemoglobin-Based Oxygen Carriers Indicates Support for Continued ... Investigational Use Where Blood Is Not an Option, ... BPUR ) announced today that the Company,s strategy to ... HBOC-201, when blood is not an option was reinforced ...
Cached Medicine News:Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 2Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 3Health News:Providing Affordable Health Care Coverage Cited as a Top Priority, Commissioner Says 2Health News:Open Hearings, Fact-Finding Today by SEIU Long Term Care Workers Continues Democratic Process Begun in 2006 2Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 2Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 3Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 4Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 5Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 6Health News:Immune system pathway identified to fight allergens, asthma 2Health News:Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop 2Health News:Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop 3Health News:Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop 4
... bags are part of the Freedom ... of leg bags, kits, and accessories ... of our customers. These leg bags ... constructed of 100% latex-free soft, textured ...
... part of the Freedom Urinary Collection ... bags, kits, and accessories designed to ... customers. These leg bags are offered ... 100% latex-free soft, textured medical grade ...
... Freedom leg bags are part of ... versatile line of leg bags, kits, ... varied needs of our customers. These ... sizes, and constructed of 100% latex-free ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: